The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
Anyone saying the PreCision platform has been overlooked yet again is misleading this BB...
Firstly, we already have a PreCision deal in place with Point Biopharma.
https://avacta.com/license-agreement-with-point-biopharma-inc/
Point Biopharma have just been acquired by Eli Lilly.
https://investor.lilly.com/news-releases/news-release-details/lilly-completes-acquisition-point-biopharma
'Cryptophycin-52 (Cr-52, LY355703, 11) was designed by Eli Lilly, and its reported potency is 40- to 400-fold greater than that of paclitaxel or vinca alkaloids, making it a promising clinical candidate [111,112,113,114]. The mechanism of action involves suppressing microtubule dynamics and arresting cells in the G2/M phase. However, the co-crystallization data between Cr-52 and tubulin has not yet been solved, and the details of the binding site remain elusive. The Cr-52 structure is an analogue to cryptophycin-1, containing two hydroxy acids (units A and D) and two amino acids (units B and C). Due to the steric hindrance of the geminal dimethyl group, it is more resistant against ester hydrolysis than are cryptophycin-1 derivatives [103]. After numerous preclinical studies, Eli Lilly advanced Cr-52 to clinical trials, with aims to define the MTD, recommended dose, pattern of toxicity, and pharmacokinetic profile. Two Phase I clinical trials were performed, and a dose of 1.5 mg/m2 was recommended for Phase II evaluation on a day 1 and 8 schedule every 21 days [111].
Despite these findings, the treatment effect for NSCLC was not achieved as expected. Twenty-six patients were enrolled, of whom 25 were evaluable for toxicity and response. There were no responders when the weekly dose was lowered from 1.5 mg/m2 to 1.125 mg/m2. Median survival was 4.1 months, and toxicity was predominantly neurologic in the form of peripheral neuropathy and constipation [113]. Another study was performed to determine the activity of LY355703 and to characterize its toxicity profile in patients with platinum-resistant advanced ovarian cancer, but only modest activity was observed in these patients [114].
Cr-52 failed in Phase II clinical studies due to the lack of efficacy and its high toxicity at the chosen doses. Although the cryptophycins were unable to advance to stand-alone agents, desirable characteristics including high potency, relative hydrophilicity, lack of P-gp susceptibility, and a common resistance mechanism make it an attractive ADC payload. '
Now who'se to say Lilly might not be looking at PreCision???
And from the placing announcement RNS...note last item...FURTHER EXPAND PIPELINE'..you was told...😉 question is...are they picking them out of the hat themselves or have they been approached by one or more companies to use their products...
'pre|CISION? pre-clinical pipeline:
o Next clinical candidate to be selected Q1 2025;
o Tumour microenvironment activated drug conjugate clinical candidate to selected in the second half of 2025; and
o Further expand pipeline;'
From the AVA6000 update...
'The continuing validation of the pre|CISION? platform we are seeing in the clinic underlines our confidence in the significant opportunity to apply pre|CISION? to a range of warheads, including those much more potent than doxorubicin.'
Ice...they don't issue the TR1 Avacta does. A new investor only have to tell Avacta officially when they hold 3% then at every 1 % increase. Some companies choose to quietly forget...or delay notification if they are filling a large order for themselves and then speak out once the order is completed.
As soon as Avacta receives details of holding from the investor they notify the market with a TR1...now, if there is still a news blackout these might be held off or if an investor is currently buying more they too might be holding off.
We need to know who the European guys are...
'As a result of the Offer Price being less than 95 per cent. of the VWAP in the five-day trading period prior to the announcement of the Placing, the Direct Subscription and the REX Offer, the conversion price (118.75 pence) and the reset floor price (95 pence) will be recalculated by the calculation agent using an adjustment factor calculation as follows:
1. the adjustment factor will be (A+B)/(A+C), where:
1. A = number of Shares in issue immediately before the date of first public announcement of the terms (the "Pricing Date") of the Bookbuild;
2. B = aggregate gross proceeds of the Bookbuild divided by the Current Market Price ("CMP") on the Pricing Date of the Bookbuild, where CMP on the Pricing Date = arithmetic average of the five daily VWAPs immediately preceding the Pricing Date; and
3. C = number of Shares comprised in the Bookbuild.
The principal remaining under the Bonds was reduced by a further £2.55 million to £38.25 million on 22 January 2024 following the fifth quarterly amortisation.'
25-Mar-24 16:32:47 50.44375 200,000 Sell* 50.50 51.00 100.89k
and a lot of sells just above the 50 mark...
I haven't sat and dne the maths but I wonder if our Bond friends will be getting their price reduced to the 50 mark...if so, then I'd say we're seeing some naughty forward selling...or a friendly sale to a mate at mates rates...
Almostrich...have you seen this from June 2025:
https://avacta.com/2015-06-11/
'Avacta anticipates that the SMDC will review the two-weekly cohort 1 data by the end of April.'
By the end of April...so C2 should start very early May...all being well the C3 in June and C4 July
Is that the aim..?
Rambo...yes I was throwing it into the mix intensionally to try and end the round and round and round...
As you say there's a big difference between Cohorts and Patients running in parallel.
The bottom line is they are aiming to be sble to speed up the whole process but as always they are totally reliant on other factors to keep it on track.
I think there's confusion here...sequentially = 1 then 2 the 3 then 4 etc...with dosage increasing as you move to the next cohort.
In the 2W the US starts with C1 @ 160
The UK starts with C2 @ 200
When US finishes C1 they start C3 @ 250
When the UK finishes C2 they start C4 @ 310
This is still classed as the same trial with the same perameters etc but they are running in parallel and the whole timeframe is speeded up...
This is how I see and how they will meet their timeframes.
For those who might not have joined the dots regarding Orphan Drug and Avactas decision to commercialise AVA6000 themselves...
'Designation of a drug as an orphan drug has yielded medical breakthroughs that might not otherwise have been achieved, due to the economics of drug research and development.[1] Examples of this can be that in the U.S. and the EU, it is easier to gain marketing approval for an orphan drug. There may be other financial incentives, such as an extended period of exclusivity, during which the producer has sole rights to market the drug. All are intended to encourage development of drugs which would otherwise lack sufficient profit motive to attract corporate research budgets and personnel.'